We are currently doing a project with the aim to analyse new companies which are developing disease management tools (DMT) of Alzheimer and Dementia. The objective of this project is to gain understanding in how these new companies can change and improve the management process of the disease.
We are still in the early process of the project but can share some of the insights we have so far. Below is conceptual summary of the current thinking regarding the different tools.
At first, one may react about the absence of the GP and specialist doctors in this analysis. They have a role and we are indeed evaluating DMT’s for them as well.
The key observation we do is how the use of DMTs can shift our perspective to make it patient-centric and support the informal and formal caregivers to provide good care.
In the future, we believe the patient will be empowered to have a much more central role throughout the disease process, from the pre-clinical stage until the stage where the ability is not there anymore.
We would anticipate that the patient would have tools:
- to evaluate cognitive functions to identify decreased functionality
- to have knowledge about the disease, but also methods to prevent fear of disease progression.
- to be informed about ways to prevent disease progression through different means such as exercise, food, cognitive training, etc (if this works)
Follow this link to get an overview of the companies we have found: https://public.tableau.com/profile/mattias.kyhlstedt#!/vizhome/DMT_Dementia/Overview
